Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis
2026年9月10日 更新者:Tunç Ozen、Istanbul Medeniyet University
Microbiological Profile of Secondary Bacterial Infections and Nasal Colonization in Patients With Scabies and Atopic Dermatitis: A Prospective Observational Study
This prospective observational study will evaluate the microbiological profile of secondary bacterial infection and nasal colonization in participants with scabies or atopic dermatitis.
Bacteria isolated from impetiginized skin lesions and nasal swabs will be compared, and antimicrobial susceptibility patterns will be assessed.
Healthy participants without an inflammatory skin disease or signs of infection will provide nasal swabs as a control group.
Patients will be followed on days 7 and 14 to assess clinical response and related clinical measures.
研究概览
地位
尚未招聘
条件
详细说明
Participants with dermatologist-confirmed scabies or atopic dermatitis and active impetiginized skin lesions will undergo clinical assessment and microbiological sampling.
A superficial swab will be obtained from the infected skin lesion and a nasal swab will be obtained from the nasal vestibules.
Healthy controls will undergo nasal sampling only.
Cultures will be evaluated for Staphylococcus aureus, Streptococcus pyogenes, and other bacterial isolates.
Antimicrobial susceptibility testing will be performed according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidance.
Skin and nasal isolates will be compared at the species level and by antimicrobial resistance profile.
Clinical data include age, sex, disease duration, comorbidities, recent treatments, itch severity using a 0-10 visual analog scale, and lesion morphology, location, number, and excoriation.
Patients will be contacted on days 7 and 14 to assess clinical response, new lesion development, change in itch severity, treatment adherence, and local or systemic adverse events.
研究类型
观察性的
注册 (估计的)
51
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:TEST CONTACT - REPLACE
- 电话号码:+90 000 000 0000
- 邮箱:test-contact@example.com
学习地点
-
-
-
Istanbul、土耳其(türkiye)
- Test Study Site - Replace
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
是的
取样方法
非概率样本
研究人群
Participants presenting to a dermatology clinic will include patients with dermatologist-confirmed scabies or atopic dermatitis and active impetiginized skin lesions, as well as healthy controls without inflammatory skin disease or signs of infection.
描述
Inclusion Criteria:
- Scabies group: dermatologist-confirmed scabies and an active impetiginized skin lesion.
- Atopic dermatitis group: dermatologist-confirmed atopic dermatitis and an active impetiginized skin lesion.
- Healthy control group: no inflammatory skin disease or clinical signs of infection.
- Written informed consent (and appropriate parent/guardian permission when applicable).
Exclusion Criteria:
- Systemic or topical antibiotic use within the previous 14 days.
- Active nasal infection or nasal symptoms.
- History of nasal surgery or anatomic nasal deformity.
TEST DRAFT NOTE: The source protocol contains wording that may conflict with inclusion of healthy controls; the final eligibility text must be reconciled with the ethics-approved protocol before release.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Scabies with impetiginized lesions
Participants with dermatologist-confirmed scabies and an active impetiginized skin lesion suggestive of secondary bacterial infection.
|
|
Atopic dermatitis with impetiginized lesions
Participants with dermatologist-confirmed atopic dermatitis and an active impetiginized skin lesion suggestive of secondary bacterial infection.
|
|
Healthy controls
Participants without an inflammatory skin disease or clinical signs of infection; nasal swab sampling only.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Concordance of bacterial species between impetiginized skin lesion and nasal cultures
大体时间:At baseline (enrollment)
|
Among participants in the scabies and atopic dermatitis groups with paired evaluable skin and nasal cultures, concordance will be defined as isolation of the same bacterial species from both anatomical sites.
Species-level agreement will be summarized and evaluated using Cohen's kappa coefficient.
|
At baseline (enrollment)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Bacterial profile of impetiginized skin lesions
大体时间:At baseline (enrollment)
|
The number and proportion of lesion cultures yielding Staphylococcus aureus, Streptococcus pyogenes, other bacteria, mixed growth, or no bacterial growth will be summarized.
|
At baseline (enrollment)
|
|
Nasal Staphylococcus aureus carriage across study groups
大体时间:At baseline (enrollment)
|
The number and proportion of participants with nasal Staphylococcus aureus carriage will be summarized for the scabies, atopic dermatitis, and healthy control groups.
|
At baseline (enrollment)
|
|
Antimicrobial susceptibility and resistance profile of bacterial isolates
大体时间:At baseline (enrollment)
|
Antimicrobial susceptibility results, including methicillin resistance among Staphylococcus aureus isolates and susceptibility to the antibiotics included in the laboratory panel, will be summarized for skin and nasal isolates.
|
At baseline (enrollment)
|
|
Clinical response at day 14
大体时间:14 days after enrollment
|
Clinical response will be categorized as complete remission, partial response, no change, or worsening.
Associations with bacterial species, methicillin resistance, antimicrobial resistance, nasal carriage, and skin-nasal concordance will be explored.
|
14 days after enrollment
|
|
Development of new skin lesions during follow-up
大体时间:Through 14 days after enrollment
|
The occurrence of new lesions during the 14-day follow-up period will be recorded.
|
Through 14 days after enrollment
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:TEST INVESTIGATOR - REPLACE、TEST AFFILIATION - REPLACE
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年10月1日
初级完成 (估计的)
2027年3月1日
研究完成 (估计的)
2027年3月1日
研究注册日期
首次提交
2026年9月4日
首先提交符合 QC 标准的
2026年9月4日
首次发布 (实际的)
2026年9月10日
研究记录更新
最后更新发布 (实际的)
2026年9月15日
上次提交的符合 QC 标准的更新
2026年9月10日
最后验证
2026年9月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- SCAB-AD-NASAL-TEST-001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.